結節性痒疹治療市場：製品別、流通チャネル別、地域別、2024～2031年

結節性痒疹治療市場の評価 - 2024～2031年

結節性痒疹（PN）治療市場は、同疾患の有病率の上昇とヘルスケア従事者および患者の意識の高まりを受けて開拓が進んでいます。結節性痒疹は、かゆみを伴う結節を引き起こす持続性の皮膚疾患で、患者のQOLに大きな影響を与えます。過去10年間、診断手順の改善や皮膚科医や一般開業医によるこの疾患の認知度向上もあって、診断症例数は増加しており、2024年には13億米ドルの売上を突破し、2031年には約19億米ドルの評価額に達する見込みです。

遠隔医療やデジタルヘルスプラットフォームの利用が増加することで、皮膚科の診察や治療がより身近なものとなり、PN治療の需要拡大に寄与しています。その結果、PN治療市場は、有病率の上昇、治療法の改善、ヘルスケアサービスへの患者アクセスの改善などの複合的な要因によって大幅に拡大し、2024年から2031年にかけてCAGR 5.30%で成長すると予測されます。

結節性痒疹治療市場定義/概要

結節性痒疹（PN）は、持続的な掻破と炎症によって頻繁に生じる非常に刺激性の結節によって特徴付けられる慢性皮膚疾患です。結節性痒疹の治療は、症状の緩和、痒みの管理、患者の生活の質を高めるための根本的な原因への対処に重点を置いています。局所療法は結節性痒疹の最も一般的な治療法の一つです。コルチコステロイド、カルシニューリン阻害薬、カプサイシンローションが炎症やかゆみの治療に頻繁に使用されます。

結節性痒疹（PN）は、痒みを伴う結節を生じ、患者のQOLに大きな影響を及ぼす持続性の皮膚疾患です。結節性痒疹は、症状管理、痒みの緩和、皮膚病変の改善に焦点を当てた様々な技術を用いて治療されます。局所療法は結節性痒疹治療の最も一般的な適応の一つです。これにはコルチコステロイド、カルシニューリン阻害剤、カプサイシンクリームなどが含まれます。

PN管理の将来は、薬理学的手法と非薬理学的手法を組み合わせた統合的アプローチが必要になる可能性が高いです。PNの心理的影響に関する参考資料が増えるにつれ、行動療法、ストレス管理、生活習慣の改善を含む包括的な治療戦略が広く受け入れられるようになってきています。

カプサイシンクリームの需要増加は製品セグメントに影響を与えるか？

カプサイシンクリームの需要拡大は、結節性痒疹治療市場、特に製品セグメントにおける主要な促進要因です。唐辛子由来のカプサイシンは、結節性痒疹に伴う激しいかゆみの治療に有望視されています。結節性痒疹の有病率の増加は、この需要の主な促進要因です。Journal of the American Academy of Dermatologyに掲載された調査によると、米国における結節性痒疹の推定有病率は10万人あたり72例です。これは、米国だけでもおよそ23万人がこの病気の影響を受けていることになります。全米湿疹協会によると、PNは一般社会では4,000人に1人の割合で罹患しており、その広範な有病率を示しています。

国立生物工学情報センター（NCBI）によると、臨床試験において、カプサイシンクリームを投与された患者の33％が、プラセボ群ではわずか7％であったのに対し、そう痒症の有意な減少を報告しました。このことは、カプサイシンがPN症状の治療に有用である可能性を示しています。さらに、自然薬や市販薬への関心の高まりが、カプサイシンクリームの市場を押し上げています。米国皮膚科学会は、外用カプサイシンは処方箋なしで入手可能であるため、多くの人々にとって実行可能な選択肢になると指摘しています。

有資格ヘルスケア専門家の不足は結節性痒疹治療市場の妨げになるか？

結節性痒疹治療市場は、熟練したヘルスケア従事者の不足によって阻害される可能性がありますが、様々な要因がこの潜在的な障壁を緩和する可能性があります。大きな要因の一つは、結節性痒疹（PN）の世界の有病率の上昇です。過少診断のため正確な数は限られているが、調査によると米国では10万人あたり約72人がPNに罹患しています。頻度の増加により、治療の選択肢と専門家に対する需要が高まっています。さらに、診断方法の進歩により、PN患者の発見が容易になりつつあります。例えば、Journal of the American Academy of Dermatologyに掲載された2022年の研究では、ダーモスコピーは臨床検査のみと比較して、PNの診断精度を23％向上させることが発見されました。

この大きな経済効果は、治療開発と専門トレーニングへの投資を促進すると予想されます。さらに、FDAが2022年にPN治療薬としてデュピルマブを承認したことで、この市場領域に対する認識と関心が高まっています。全米湿疹協会によると、デュピルマブは臨床試験でかゆみの程度を60％軽減し、多くのPN患者の生活の質を高める可能性があるといいます。ヘルスケア人材の不足は依然として懸念材料ですが、いくつかの市場要因がその影響を相殺する一助となると思われます。労働力問題にもかかわらず、疾患に対する意識の高まり、経済的インセンティブ、治療の改善は、より多くの専門医をこの分野に引きつけ、市場の拡大を促進するはずです。しかし、市場の潜在力を十分に発揮させるには、ヘルスケア人材の不足に対処することが不可欠です。

目次

第1章 結節性痒疹治療の世界市場イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の結節性痒疹治療市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 結節性痒疹治療の世界市場：製品別

• 概要
• 抗ヒスタミン薬
• カプサシンクリーム
• 副腎皮質ステロイド
• エモリエント剤
• その他

第6章 結節性痒疹治療の世界市場：流通チャネル別

• 概要
• 小売薬局
• 病院薬局
• オンライン薬局

第7章 結節性痒疹治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界の結節性痒疹治療市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第9章 企業プロファイル

• Bayer AG
• Galderma SA（Nestle Skin Health Company）
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc
• VYNE Therapeutics, Inc.
• Trevi Therapeutics, Inc
• Merck & Co., Inc.
• Novartis AG
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson

第10章 付録

• 関連調査

Prurigo Nodularis Treatment Market Valuation - 2024-2031

The Prurigo Nodularis (PN) therapy market is developing in response to the condition's increasing prevalence and rising awareness among healthcare practitioners and patients. Prurigo nodularis is a persistent skin illness that causes itchy nodules and has a major impact on a patient's quality of life. Over the last decade, there has been an increase in the number of diagnosed cases, partially due to improved diagnostic procedures and increased recognition of the disorder by dermatologists and general practitioners by enabling the market to surpass a revenue of USD 1.30 Billion valued in 2024 and reach a valuation of around USD 1.90 Billion by 2031.

The increasing use of telemedicine and digital health platforms makes dermatological consultations and treatments more accessible which contributes to the growing demand for PN therapies. As a result, the PN treatment market is predicted to expand significantly driven by a combination of rising illness prevalence, therapeutic improvements, and improved patient access to healthcare services by enabling the market to grow at a CAGR of 5.30% from 2024 to 2031.

Prurigo Nodularis Treatment Market: Definition/ Overview

Prurigo nodularis (PN) is a chronic skin disorder distinguished by very irritating nodules that are frequently caused by persistent scratching and inflammation. Prurigo nodularis treatment focuses on symptom relief, itch management, and addressing underlying causes to enhance the patient's quality of life. Topical therapies are one of the most common methods for treating PN. Corticosteroids, calcineurin inhibitors, and capsaicin lotions are frequently used to treat inflammation and itching.

Prurigo nodularis (PN) is a persistent skin ailment that causes itchy nodules and has a major influence on a patient's quality of life. Prurigo nodularis is treated using a variety of techniques focused on symptom management, itch relief, and skin lesion improvement. Topical therapies are one of the most common applications for PN therapy. These include corticosteroids, calcineurin inhibitors, and capsaicin creams.

The future of PN management will most likely involve an integrated approach that combines pharmacological and non-pharmacological techniques. As more is learned about the psychological impact of PN, comprehensive treatment strategies that include behavioral therapy, stress management, and lifestyle changes are becoming more widely accepted.

Will Increasing Demand for Capsaicin Cream Influence the Product Segment?

The growing demand for capsaicin cream is a major driver in the prurigo nodularis treatment market, particularly within the product segment. Capsaicin, derived from chili peppers has shown promise in treating the severe itching associated with prurigo nodularis. The increasing prevalence of prurigo nodularis is a major driver of this demand. According to research published in the Journal of the American Academy of Dermatology, the estimated prevalence of PN in the United States is 72 instances per 100,000 individuals. This equates to roughly 230,000 people impacted by this illness in the United States alone. According to the National Eczema Association, PN affects around one in every 4,000 people in the general community demonstrating its widespread prevalence.

According to the National Center for Biotechnology Information (NCBI) in a clinical trial, 33% of patients receiving capsaicin cream reported a significant reduction in pruritus compared to only 7% in the placebo group. This illustrates capsaicin's potential usefulness in treating PN symptoms. Furthermore, the growing interest in natural and over-the-counter medicines is driving up the market for capsaicin cream. The American Academy of Dermatology points out that topical capsaicin is available without a prescription making it a viable alternative for many people.

Will Lack of Qualified Healthcare Professionals Hamper the Prurigo Nodularis Treatment Market?

The prurigo nodularis treatment market may be hampered by a lack of skilled healthcare practitioners, however, various factors may mitigate this potential barrier. One major factor is the rising global prevalence of prurigo nodularis (PN). While exact numbers are limited due to underdiagnosis, research indicates that PN affects roughly 72 per 100,000 persons in the United States. The increased frequency necessitates a greater demand for treatment choices and professionals. Furthermore, advances in diagnostic procedures are enhancing the detection of PN patients. For example, a 2022 study published in the Journal of the American Academy of Dermatology discovered that dermoscopy improved diagnostic accuracy for PN by 23% when compared to clinical examination alone.

This significant economic impact is expected to drive investment in treatment development and specialized training. Furthermore, the FDA's approval of dupilumab for PN therapy in 2022 has raised awareness and interest in this market area. According to the National Eczema Association, dupilumab showed a 60% reduction in itch severity in clinical studies, potentially enhancing the quality of life for many PN sufferers. While the scarcity of healthcare personnel remains a worry, several market factors may assist in offsetting its effects. Despite labor issues, increasing disease awareness, economic incentives, and treatment improvements should attract more specialists to the sector and drive market expansion. However, addressing the healthcare personnel deficit is critical to fully fulfilling the market's potential.

Category-Wise Acumens

Will Widespread Use and Trust in Corticosteroids Influence the Product Segment?

Corticosteroids dominate the market owing to their demonstrated usefulness in regulating inflammation and lowering itching caused by the illness. Dermatologists frequently prescribe corticosteroids as the first line of treatment. They are available in topical, oral, and injectable forms. They operate by inhibiting the immunological response that causes itchy nodules resulting in great alleviation for patients. Topical corticosteroids are especially popular because they may be applied directly to the afflicted areas providing localized treatment with less systemic adverse effects than oral or injectable alternatives. Corticosteroids' broad use and trust supported by multiple clinical research and decades of medical practice solidifies their dominance in the PN therapy market.

Corticosteroids' dominance in the PN therapy market is driven not only by their efficacy but also by their availability. These drugs are readily available and come in a variety of dosages and formulations making them appropriate for different stages and severity levels of PN. This flexibility enables healthcare providers to adjust treatment strategies to particular patient demands, hence improving treatment outcomes. Furthermore, corticosteroids are frequently covered by insurance programs which reduces patients' financial burden and encourages treatment adherence.

Will the Rising Preference for Medications Drive Growth in the Distribution Channel Segment?

The retail pharmacies category is expected to have the highest compound annual growth rate (CAGR) in the prurigo nodularis treatment market over the forecast period. This dominance is partly due to an increasing propensity for obtaining pharmaceuticals from retail pharmacies which is heavily affected by their accessibility and convenience. Retail pharmacies are frequently more accessible to patients than hospitals or online pharmacies as they have longer hours and are placed in convenient neighborhood locations. This makes them the first choice for many people who need fast relief from the symptoms of prurigo nodularis which can be quite uncomfortable and debilitating.

Retail pharmacies frequently offer numerous incentives to attract patients such as discounts and loyalty programs. These cost-cutting approaches are especially tempting to patients who need long-term treatment for chronic illnesses such as prurigo nodularis. The economic benefits provided by retail pharmacies can greatly lessen patient's financial burden encouraging them to continue their therapy uninterrupted. This is especially critical in the treatment of prurigo nodularis where strict adherence to prescribed medication regimens is required for successful symptom control and flare-up avoidance.

Country/Region-wise Acumens

Will the Rising Disease Awareness Drive the Growth in the Asia Pacific Region?

The Asia Pacific region is expected to see considerable growth in the Prurigo Nodularis (PN) treatment market owing to increase in illness awareness and improved healthcare infrastructure. As more people and healthcare providers become aware of the signs and effects of PN, there is a greater desire for effective treatments. According to research published in the Journal of the American Academy of Dermatology, the frequency of PN in Asia varies between 0.1% and 3.8% of the population depending on the country and demography. This incidence combined with the massive population bases in countries such as China and India indicates a significant potential market for PN treatments.

Organizations such as the International Forum for the Study of Itch (IFSI) and the Asian Academy of Dermatology and Venereology (AADV) have played an important role in educating both patients and healthcare professionals about PN contributing to the increase in disease awareness. According to World Health Organization (WHO) research, dermatological disorders including PN are becoming more widely recognized as serious health concerns in the Asia Pacific region with a 15% increase in reported cases in the last five years.

Will the Rising Healthcare Expenditures and a Growing Patient Population Boost the Market in the North American Region?

The prurigo nodularis (PN) treatment market in North America is expected to increase significantly owing to many main factors. One of the main drivers is the region's increase in healthcare expenses. According to the Centers for Medicare and Medicaid Services (CMS), U.S. healthcare spending will exceed USD 4.3 Trillion in 2021, up 2.7% from 2020. This trend of increase in healthcare spending is anticipated to continue with forecasts indicating that it would reach USD 6.2 Trillion by 2028. The significant investment in healthcare infrastructure and research creates an enabling environment for the development and implementation of novel PN treatments. Furthermore, the expanding patient population is a key driver of market expansion.

Another key cause is the growing awareness and diagnosis of PN. The National Eczema Association has been actively striving to increase awareness of PN and other associated disorders resulting in better recognition and diagnosis. This, together with developments in diagnostic procedures is expected to enhance the identified patient pool accelerating market expansion. The market also benefits from ongoing R&D initiatives. The National Institutes of Health (NIH) has financed various research on PN, and clinicaltrials.gov lists more than 20 active or recruiting clinical trials for PN treatments as of 2024. This extensive pipeline of prospective therapies is projected to provide more effective treatment alternatives, hence supporting market growth.

Competitive Landscape

The prurigo nodularis treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the prurigo nodularis treatment market include:

Bayer AG

Galderma SA (Nestle Skin Health Company)

Pfizer, Inc.

Sanofi SA

Takeda Pharmaceutical Company Limited

GlaxoSmithKline Plc

VYNE Therapeutics, Inc.

Trevi Therapeutics, Inc

Merck & Co., Inc.

Novartis AG

Celgene Corporation

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Latest Developments

In February 2023, Pfizer is planning an unprecedented number of pharmaceutical launches with the corporation expected to release 19 new drugs over the next 18 months.

In June 2023, Novartis announced that it has agreed to acquire Chinook Therapeutics, a Seattle, WA-based clinical-stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed-upon deal is subject to customary closing conditions and is fully consistent with Novartis' strategy to focus on innovative medicines. It will significantly expand its renal portfolio, complementing the existing pipeline.

Prurigo Nodularis Treatment Market, By Category

• Product:
• Antihistamines
• Capsaicin Cream
• Corticosteroids
• Emollients
• Others
• Distribution Channel:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRURIGO NODULARIS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRURIGO NODULARIS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antihistamines
• 5.3 Capsacin Cream
• 5.4 Corticosteroids
• 5.5 Emollients
• 5.6 Others

6 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Retail Pharmacies
• 6.3 Hospital Pharmacies
• 6.4 Online Pharmacies

7 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL PRURIGO NODULARIS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Bayer AG
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Galderma SA (Nestle Skin Health Company)
• 9.3 Pfizer, Inc.
• 9.4 Sanofi SA
• 9.5 Takeda Pharmaceutical Company Limited
• 9.6 GlaxoSmithKline Plc
• 9.7 VYNE Therapeutics, Inc.
• 9.8 Trevi Therapeutics, Inc
• 9.9 Merck & Co., Inc.
• 9.10 Novartis AG
• 9.11 Celgene Corporation
• 9.12 Teva Pharmaceutical Industries Ltd.
• 9.13 Johnson & Johnson

10 Appendix

• 10.1 Related Research